[go: up one dir, main page]

SV2018005701A - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer - Google Patents

Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer

Info

Publication number
SV2018005701A
SV2018005701A SV2018005701A SV2018005701A SV2018005701A SV 2018005701 A SV2018005701 A SV 2018005701A SV 2018005701 A SV2018005701 A SV 2018005701A SV 2018005701 A SV2018005701 A SV 2018005701A SV 2018005701 A SV2018005701 A SV 2018005701A
Authority
SV
El Salvador
Prior art keywords
ilo
tiadiazol
compounds
cancer treatment
methyl
Prior art date
Application number
SV2018005701A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Johannes Wilhelmus Maria Nissink
Mark David Charles
James Matthew Wood
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of SV2018005701A publication Critical patent/SV2018005701A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN COMPUESTO DE FÓRMULA (I): (VER FORMULA) O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE: Q PUEDE SER 5-METILPIRIDAZIN-3-ILO, 5-CLOROPIRIDAZIN-3- ILO, 6-METILPIRIDAZIN-3-ILO, O 6-FLUOROPIRIDAZIN-3-ILO; R PUEDE SER HIDRÓGENO, FLÚOR, O METOXI; R1 PUEDE SER HIDRÓGENO, METOXI, DIFLUOROMETOXI, O TRIFLUOROMETOXI; Y R2 PUEDE SER METILO O ETILO. EL COMPUESTO DE FÓRMULA (I) PUEDE INHIBIR LA GLUTAMINASA, POR EJEMPLO, GLS1.
SV2018005701A 2015-11-30 2018-05-29 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer SV2018005701A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30

Publications (1)

Publication Number Publication Date
SV2018005701A true SV2018005701A (es) 2018-11-27

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005701A SV2018005701A (es) 2015-11-30 2018-05-29 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer

Country Status (25)

Country Link
US (1) US9938265B2 (es)
EP (1) EP3383871B1 (es)
JP (1) JP6873132B2 (es)
KR (1) KR20180083412A (es)
CN (1) CN108349967B (es)
AR (1) AR106876A1 (es)
AU (1) AU2016363719B2 (es)
BR (1) BR112018010812A2 (es)
CA (1) CA3005516C (es)
CL (1) CL2018001408A1 (es)
CO (1) CO2018006929A2 (es)
DK (1) DK3383871T3 (es)
DO (1) DOP2018000134A (es)
EA (1) EA201891240A1 (es)
ES (1) ES2759940T3 (es)
IL (1) IL258644A (es)
MX (1) MX2018006528A (es)
NI (1) NI201800065A (es)
PE (1) PE20181450A1 (es)
PH (1) PH12018501132A1 (es)
SG (1) SG11201803813UA (es)
SV (1) SV2018005701A (es)
TN (1) TN2018000126A1 (es)
TW (1) TW201730188A (es)
WO (1) WO2017093300A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2939506T3 (es) * 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777824B2 (en) * 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
WO2010121918A1 (en) * 2009-04-20 2010-10-28 F. Hoffmann-La Roche Ag Proline derivatives as cathepsin inhibitors
HRP20192144T1 (hr) * 2011-11-21 2020-02-21 Calithera Biosciences Inc. Heterociklični inhibitori glutaminaze
LT2920168T (lt) * 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterociklinis gliutaminazės inhibitorius
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
JP6666263B2 (ja) * 2014-01-06 2020-03-13 ライゼン・ファーマシューティカルズ・エスアー グルタミナーゼの新規阻害剤
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
EA201891240A1 (ru) 2018-11-30
KR20180083412A (ko) 2018-07-20
JP6873132B2 (ja) 2021-05-19
DK3383871T3 (da) 2019-12-16
EP3383871A1 (en) 2018-10-10
MX2018006528A (es) 2019-05-15
PH12018501132A1 (en) 2019-01-21
CL2018001408A1 (es) 2018-10-12
AU2016363719A1 (en) 2018-07-05
PE20181450A1 (es) 2018-09-12
TW201730188A (zh) 2017-09-01
CO2018006929A2 (es) 2018-10-10
JP2019501134A (ja) 2019-01-17
AU2016363719A8 (en) 2018-07-12
EP3383871B1 (en) 2019-09-11
CN108349967A (zh) 2018-07-31
DOP2018000134A (es) 2018-06-30
ES2759940T8 (es) 2020-05-20
CA3005516C (en) 2024-04-16
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
CA3005516A1 (en) 2017-06-08
IL258644A (en) 2018-06-28
TN2018000126A1 (en) 2019-10-04
AR106876A1 (es) 2018-02-28
BR112018010812A2 (pt) 2018-11-27
US20170152254A1 (en) 2017-06-01
AU2016363719B2 (en) 2019-11-14
SG11201803813UA (en) 2018-06-28
CN108349967B (zh) 2022-02-15
NI201800065A (es) 2018-10-18
ES2759940T3 (es) 2020-05-12

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
CR20160099A (es) Formulación de inhibidores de la syk
AR103680A1 (es) Inhibidores selectivos de bace1
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
NI201800071A (es) Compuestos de isoindol
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
CO2017007940A2 (es) Péptidos antagonistas prgc
MX2018001355A (es) Uso de 2-(5s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida en el tratamiento de convulsiones.